C

CytomX Therapeutics

D
CTMX
USD
-0.005
(-0.4976%)
Market Closed
45,664.00
Volume
-0.11
EPS
-
Div Yield
6.86667
P/E
78,109,789.24
Market Cap
Today
-0.4976%
1 Week
-0.010%
1 Month
-13.802%
6 Months
-75.493%
12 Months
-23.085%
Year To Date
-35.490%
All Time
0%
News

Honda’s Profits Slide From Poor Car Sales in China

06.11.2024
Stocks news

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

BYD's Rapid Rise Has Tesla in A Spin

30.05.2024
Stocks news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news

Tesla Sales Drop Amid Intensifying EV Competition

03.04.2024
Stocks news
More
Related Instruments
MRK
MRK
-0.89
(-0.872%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
PFE
PFE
0.135
(0.4941%)
USD
GILD
GILD
6.23
(6.7946%)
USD
AMGN
AMGN
0.28
(0.087%)
USD
LLY
LLY
-2.235
(-0.2794%)
USD
REGN
REGN
8.505
(1.0417%)
USD
B
BIIB
-0.32
(-0.1837%)
USD
VRTX
VRTX
9.22
(1.869%)
USD

Title:
CytomX Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Do you need help or have a question?
Contact Us